Comparison of postoperative outcomes following endoscopic third ventriculostomy or shunt in a propensity score matched pediatric cohort

倾向评分匹配的儿科队列中,比较内镜下第三脑室造瘘术或分流术后的结局

阅读:1

Abstract

PURPOSE: Thirty-day readmission and reoperation are widely used quality metrics. Endoscopic third ventriculostomy (ETV) is favored when feasible, but may compare unfavorably with shunt in the short-term. This study analyzes 30-day outcomes of ETV and shunt surgery in comparable populations. METHODS: Data regarding patients undergoing ETV or initial shunt insertion were extracted from the National Surgical Quality Improvement Program - Pediatric for 2013-2020. Patients were stratified into three age groups: ≤ 6 months (N = 5,906), 6 months-2 years (N = 2,364), and ≥ 2 years (N = 4,408). Characteristics were compared before and after propensity-score matching. Outcome comparisons included CNS complications, mortality, readmission, and reinterventions. RESULTS: There were 10,135 shunt insertions and 2,543 ETVs. After matching, patients ≤ 6 months undergoing ETV had more seizures (ETV 6.3% vs shunt 0.4%, p < 0.001), readmission (ETV 15.7% vs shunt 6.1%, p < 0.001), and reintervention (ETV 17.4% vs shunt 4.8%, p < 0.001). Among patients 6 months-2 years, ETV increased seizures (ETV 3.3% vs shunt 1.0%, p = 0.01), readmission (ETV 14.9% vs shunt 7.8%, p < 0.001), and reintervention (ETV 13.0% vs shunt 5.4%, p < 0.001). Among older patients, ETV had decreased median length of stay (ETV 3 days, IQR 1-6 days vs shunt 3 days, IQR 2-8 days, p = 0.0019) and mortality (ETV 0.4% vs shunt 1.5%, p = 0.007). CONCLUSION: Outcomes following shunt surgery and ETV in matched patients appear to be age-dependent. Younger patients undergoing ETV encountered more short-term complications. 30-day outcomes may be misleading as a quality measure in the management of childhood hydrocephalus.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。